Streetbeat News

Revenues

RAIL

FreightCar America has projected its FY23 revenue to be between $365M and $380M, which is lower than the estimated $418.5M.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:53 pm

GH

Guardant Health has raised its full year 2023 revenue guidance to $553M-$556M, representing a growth of 23% to 24% compared to 2022. The company also expects 2023 operating expenses to be lower than 2022 due to efficiency measures and leveraging of existing infrastructure. However, free cash flow is expected to be approximately negative $350 million in 2023.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:50 pm

NEO

NeoGenomics has projected its FY23 revenue to be between $585M and $592M, which is higher than the estimated $573.19M.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:49 pm

DCGO

DocGo has raised its 2023 revenue guidance to $615M-$625M, up from a previous range of $540M-$550M. The company also increased its adjusted EBITDA guidance to $50M-$55M, up from a previous range of $48M-$53M.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:47 pm

ADEA

Adeia has projected its FY23 revenue to be between $385M and $395M, which is in line with the estimated $390.26M.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:44 pm

SNTI

Senti Biosciences (NASDAQ:SNTI) has announced a strategic collaboration with China-based biotech company Celest Therapeutics for the clinical development of SENTI-301A, a therapy for solid tumors, in China. Celest will lead clinical development, operations, and manufacturing with technical support from Senti Bio. The first patient is expected to be enrolled in China in 1H 2024. Senti Bio could receive up to $156 million in milestone payments and potential tiered royalty payments. Senti Bio retains all commercialization rights outside of mainland China, Hong Kong, Macau, and Taiwan for SENTI-301A.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:41 pm

TASK

TaskUs reported better-than-expected Q3 financial results and issued Q4 and FY23 revenue guidance above estimates, leading to a rise in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:39 pm

MED

Medifast has provided its FY23 guidance, expecting EPS to be between $8.65 and $9.55, compared to the estimated $8.52. The company also anticipates revenue to be in the range of $1.05B to $1.07B, lower than the estimated $1.09B. The guidance assumes a 20.5% to 21.5% effective tax rate.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:35 pm

TMDX

TransMedics Group has projected its FY23 revenue to be between $222M and $230M, which is higher than the estimated $194.18M.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:34 pm

COMP

Compass has projected its Q4 revenue to be between $1.1 billion and $1.2 billion, which is in line with the estimated $1.17 billion.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:29 pm